Quarterly report [Sections 13 or 15(d)]

Summary of Significant Accounting Policies

v3.26.3
Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2026
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 2 – Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying condensed financial statements are unaudited. These unaudited interim condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these unaudited interim condensed financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on March 2, 2026 (the “2025 Annual Report”). The balance sheet as of December 31, 2025 included herein, was derived from the audited financial statements as of that date.

 

In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments necessary to fairly present the Company’s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily indicative of fiscal year-end results.

 

The comparative financial information for the three and nine months ended September 30, 2025 reflects the restatement described in Note 10 to the Company’s financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2025.

 

Accounting Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include management’s estimates for continued liquidity, accruals for potential liabilities, assumptions used in deriving the fair value of warrant liabilities, valuation of equity instruments issued for debt and services and realization of deferred tax assets.

 

Cash Equivalents

 

The Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in the accompanying unaudited condensed financial statements. At September 30, 2026 and December 31, 2025, total cash equivalents which consist of money market funds, amounted to approximately $8.3 million and $3.9 million, respectively.

 

Cash equivalents consist entirely of investments in U.S. Treasury money market funds that are not insured by the FDIC; however, these funds invest solely in direct obligations of the U.S. government. The Company believes that the credit risk associated with these instruments is minimal.

 

Restricted Cash

 

As of September 30, 2026, the Company has classified certain cash balances as restricted cash in its unaudited condensed balance sheets. The Company’s restricted cash is deposited in a financial institution and held as collateral for a credit card agreement with the same financial institution.

 

Deferred Offering Costs

 

The Company capitalizes the fair value of equity instruments granted and certain legal, accounting and other third-party fees that are directly related to the Company’s in-process equity financings until such financings are consummated. After consummation of an equity financing, these costs are recorded in stockholders’ equity as a reduction of additional paid-in capital generated as a result of the offering. Should a planned equity financing be abandoned, terminated or significantly delayed, the deferred offering costs are immediately written off to operating expenses. As of September 30, 2026, there was $444,000 of deferred offering costs on the balance sheet.

 

Common Stock (September 2026 Reverse Stock Split)

 

On September 8, 2026, the Company effectuated a reverse stock-split of its Common Stock, at a ratio of 1 for 25. The shares of Common Stock began trading on a reverse stock-split-adjusted basis on The Nasdaq Capital Market on September 8, 2026 under the existing trading symbol “GTBP.”

 

As a result of the reverse stock split, every twenty-five (25) shares of issued and outstanding Common Stock were automatically combined into one issued and outstanding share of Common Stock, without any change in the par value per share. No fractional shares will be issued in connection with the reverse stock split. Stockholders who otherwise would be entitled to receive fractional shares of Common Stock received their pro-rata portion of the net proceeds obtained from the aggregation and sale by the exchange agent of the fractional shares resulting from the reverse stock-split (reduced by any customary brokerage fees, commission and other expenses). The reverse stock split reduced the number of shares of Common Stock outstanding on the effective date of the reverse stock-split from 45,109,497 pre-split shares to 1,804,379 post-split shares, subject to minor adjustments due to the treatment of fractional shares.

 

Simultaneously with the reverse stock split, the total authorized shares of capital stock were reduced from 265,000,000 shares to 26,500,000 shares, consisting of 25,000,000 shares of Common Stock and 1,500,000 shares of preferred stock.

 

Proportionate adjustments have been made to the Company’s outstanding convertible securities, warrants, stock options and restricted stock. The number of shares of Common Stock into which these outstanding securities are convertible or exercisable will be adjusted proportionately as a result of the reverse stock split. The conversion prices of any outstanding convertible securities and the exercise prices of any outstanding warrants or stock options will also be proportionately adjusted in accordance with the terms of those securities and the Company’s equity incentive plans.

 

 

All share and per share information within this report has been adjusted to retroactively reflect the reverse stock-split as of the earliest period presented.

 

Stock-Based Compensation

 

The Company periodically issues stock-based compensation to officers, directors, employees, and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date.

 

Stock-based payments to officers, directors, employees, and consultants in exchange for goods and services, which include grants of employee stock options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, Compensation-Stock Compensation. Stock based payments to officers, directors, employees, and consultants, which are generally time vested, are measured at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.

 

Research and Development Expenses

 

Costs incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research and development of the Company’s products are included in research and development expenses. Purchased materials that do not have an alternative future use are also expensed. Purchased materials that have an alternative future use are classified as a prepaid expense and periodically reviewed.

 

Net Loss Per Share

 

Basic earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and warrants, the conversion of Series L 10% Convertible Preferred Stock (the “Series L Preferred Stock”), and the conversion of Series M 10% Convertible Preferred Stock (the “Series M Preferred Stock”), have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.

 

During the nine months ended September 30, 2026, the Company recorded dividends on Series L and Series M Preferred Stock of $229,000, which has been deducted from net income to arrive at net income attributable to Common Stockholders for the purpose of calculating basic and diluted earnings per share.

 

The following Common Stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:

 

   

September 30, 2026

(Unaudited)

   

September 30, 2025

(Unaudited)

 
Series L Preferred Stock 1     36,347  1     305,992  2 
Series M Preferred Stock 3     1,175,657       —  
Greenshoe Rights - Series L Preferred Stock    

1,165,934

 1    

1,420,098

 2
Greenshoe Rights - Series M Preferred Stock 3    

5,684,527

      —  
Options to purchase Common Stock     23,902       23,902  
Warrants to purchase Common Stock     9,393,734       1,978,375  
Total anti-dilutive securities     17,480,101       3,728,367  

 

1 As of September 30, 2026, the shares of Series L Preferred Stock are convertible into shares of Common Stock at the holder’s option using a conversion price of $11.35 per share.
   
2

As of September 30, 2025, the shares of Series L Preferred Stock are convertible into shares of Common Stock at the holder’s option using a conversion price of $16.05 per share.

   
3 As of September 30, 2026, the shares of Series M Preferred Stock are convertible into shares of Common Stock at the holder’s option using a conversion price of $6.10 per share.

 

Concentration

 

Cash is deposited in two financial institutions. The cash balance in one of these financial institutions is not insured by any agency. The cash balance held at the other financial institution at times may be in excess of Federal Deposit Insurance Corporation (“FDIC”) insurance limits of up to $250,000. Management believes that the financial institutions that hold the Company’s cash are financially sound and, accordingly, minimal credit risk exists.

 

 

Segment Information

 

The Company’s Chief Executive Officer and President (“CEO”) is our chief operating decision maker (“CODM”) and evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated basis. Because our CODM evaluates financial performance on a consolidated basis, the Company has determined that it operates as a single reportable segment composed of the financial results of the Company.

 

Recent Accounting Pronouncements

 

In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, requiring public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2024-03.

 

The Company’s management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does not believe the future adoption of any such pronouncements will have a material effect on the Company’s financial position and results of operations.